...has rights to develop and market Nasulin in Africa, Asia and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....

...has rights to develop and market Nasulin in Africa, Asia and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....

...has rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....

...has rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....

...and certain Asian countries, waived its Korean rights to allow for an exclusive license to Dong Sung...
...a global Phase III trial (see BioCentury, April 7). Generex Biotechnology Corp. (NASDAQ:GNBT), Toronto, Ontario Dong Sung Pharmaceutical Co. Ltd....

...holds rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Bentley Pharmaceuticals Inc. (AMEX:BNT), Exeter, N.H. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Dong Sung Pharmaceutical Co. Ltd....

...holds rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...Humulin and Humalog. Bentley Pharmaceuticals Inc. (BNT), Exeter, N.H. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Dong Sung Pharmaceutical Co. Ltd....

...Nordisk AERx iDMS inhaled insulin Ph III (A) Generex Oral-lyn; Oralin (buccal) Ph IIb (B) Bentley/Dong Sung...

...The companies partnered to develop BNT's intranasal insulin in South Korea to treat diabetes. Dong Sung will...
...Phase III trials and be responsible for regulatory submissions. Bentley Pharmaceuticals Inc. (BNT), Exeter, N.H. Dong Sung...